The table below shows Enliven Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$19.29M
-$24.13M
-$23.36M
-$20.84M
-$10.36M
-$13.02M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
$42.53M
$1.43M
-$17.89M
-$31.00K
-$194.00K
$18.30M
Dividends paid
-
-
-
-
ELVN operating cash flow (10-K history)
Enliven Therapeutics, Inc. reported operating cash flow of -$70.30M for fiscal year 2025. That is up 3.9% from -$73.19M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$21.88M (FY 2019) to -$70.30M. Figures come from the company's audited annual reports as filed with the SEC.